Under the auspices of the Melanoma World Society

Course Directors
Claus Garbe, Tuebingen, Germany
Axel Hauschild, Kiel, Germany
Daniel Vorobiof, Johannesburg, South Africa
Dagmar Whitaker, Cape Town, South Africa

Cape Town, South Africa
March 3rd–4th, 2017

SKIN CANCER UPDATE 2017
First International MWS Educational Symposium

Abstract Deadline
January 31st, 2017

www.melanomaworldsociety.org/events
WELCOME MESSAGE 1
MISSION 2
PRELIMINARY PROGRAM 3
COURSE FACULTY 8
GENERAL INFORMATION 11
SPONSORS 14
REGISTRATION FORM 15
Dear Ladies and Gentlemen,

The Melanoma World Society (MWS) is the successor organization to the WHO Melanoma Group. The latter established the World Congress of Melanoma in the years 1985–2005, conducted trials and other projects with melanoma patients. The WHO melanoma group was disbanded in 2005, as WHO did no longer financially support such expert groups. MWS was initiated at the 8th World Congress of Melanoma 2013 in Hamburg, founded in June 2014 in Munich, and registered in January 2016.

The First MWS International Educational Symposium – Skin Cancer Updated 2017 is the first of a series of educational meetings organized under the auspices of the Melanoma World Society. It is intended to organize the meeting every year in different countries.

International and national key opinion leaders on skin cancer will be invited to give an overview throughout specified presentations, to present latest clinical trial results, and to discuss on exciting new drugs, technologies and methods of treatment with the audience. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant. In addition to the scientific value of this meeting, every participant may seize the given opportunity to interact with experts in a familiar setting in one of the most interesting cities of South Africa.

Please join us for this event and submit your own studies and case presentations as free communications and as posters.

We look forward to welcoming you in Cape Town in March 2017!

With kind regards

Claus Garbe, MD  Axel Hauschild, MD
Daniel Vorobiof, MD  Dagmar Whitaker, MD

Scientific Directors
The following missions will guide the activities of MWS:

**Improve Medical Education**
MWS will host the World Congress of Melanoma every 4 years, following the tradition since 1985. MWS will care for grants in order to make attendance of physicians from developing countries possible. MWS will organize the World Meeting of Melanoma/Skin Cancer Centers yearly in between the World Congress of Melanoma. MWS will support educational meetings in countries with few experience in melanoma diagnosis and treatment.

**Improve Guideline Development**
MWS intends to unify diagnostic and therapeutic strategies in melanoma worldwide. MWS will establish a MELANOMA KNOWLEDGE DATABASE (MKD), which contains all relevant articles for evidence based medicine in melanoma, and additionally evidence tables of these articles. MKD will be accessible for all national guideline groups. MWS will organize international expert meetings in order to develop recommendations for diagnosis and treatment of melanoma in the rapidly changing landscape.

**Improve Patient’s Access to New Treatments**
MWS intends to provide melanoma patients worldwide access to new and more efficacious treatments. MWS will address governments in order to achieve a more rapid reimbursement of new treatments. MWS will address pharmaceutical companies in order to achieve access to new treatment modalities in countries, where the high prices cannot be reimbursed.

**Improve Clinical Research in Melanoma**
MWS will coordinate clinical research activities in melanoma internationally. MWS will perform international clinical trials in indications, which are not investigated by the pharmaceutical industries. MWS will support international expert meetings in order to coordinate clinical research.
**Friday, March 3rd, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–09:00</td>
<td><strong>Molecular biology of melanoma</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dirk Schadendorf, Charles Thatcher</td>
</tr>
<tr>
<td>08:00–08:15</td>
<td>Biology of melanoma: From melanocytic nevus to metastatic melanoma</td>
</tr>
<tr>
<td></td>
<td>Dirk Schadendorf, Essen, Germany</td>
</tr>
<tr>
<td>08:20–08:35</td>
<td>Molecular testing in melanoma</td>
</tr>
<tr>
<td></td>
<td>Christopher Philipp Maske, Johannesburg, South Africa</td>
</tr>
<tr>
<td>08:40–08:55</td>
<td>Panel discussion</td>
</tr>
<tr>
<td></td>
<td>Helen Gogas, Athens, Greece</td>
</tr>
<tr>
<td></td>
<td>Christopher Philipp Maske, Johannesburg, South Africa</td>
</tr>
<tr>
<td></td>
<td>Dirk Schadendorf, Essen, Germany</td>
</tr>
<tr>
<td></td>
<td>Charles Thatcher, Johannesburg, South Africa</td>
</tr>
<tr>
<td>09:00–10:00</td>
<td><strong>Epidemiology of skin cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Claus Garbe, Dagmar Whitaker</td>
</tr>
<tr>
<td>09:00–09:15</td>
<td>Global incidence of skin cancer</td>
</tr>
<tr>
<td></td>
<td>Claus Garbe, Tuebingen, Germany</td>
</tr>
<tr>
<td>09:20–09:35</td>
<td>Global mortality of melanoma</td>
</tr>
<tr>
<td></td>
<td>Jean Jacques Grob, Marseille, France</td>
</tr>
<tr>
<td>09:40–09:55</td>
<td>Melanoma in South Africa</td>
</tr>
<tr>
<td></td>
<td>Dagmar Whitaker, Cape Town, South Africa</td>
</tr>
<tr>
<td>10:00–10:30</td>
<td>Break</td>
</tr>
<tr>
<td>10:30–11:30</td>
<td><strong>Early detection of melanoma</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Axel Hauschild, Gary Levy</td>
</tr>
<tr>
<td>10:30–10:45</td>
<td>New devices for skin cancer diagnosis</td>
</tr>
<tr>
<td></td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td>10:50–11:05</td>
<td>Early detection by dermoscopy</td>
</tr>
<tr>
<td></td>
<td>Gary Levy, Johannesburg, South Africa</td>
</tr>
<tr>
<td>11:10–11:25</td>
<td>Population based skin cancer screening in Germany</td>
</tr>
<tr>
<td></td>
<td>Axel Hauschild, Kiel, Germany</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>11:30–12:30</td>
<td>Surgery</td>
</tr>
<tr>
<td>11:30–11:45</td>
<td>Surgery of non-melanoma skin cancers</td>
</tr>
<tr>
<td>11:50–12:05</td>
<td>Surgery of melanoma primaries and regional nodes</td>
</tr>
<tr>
<td>12:10–12:25</td>
<td>Panel discussion</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–12:45</td>
<td>Break</td>
</tr>
<tr>
<td>12:45–13:45</td>
<td>Satellite Symposium with lunch bags</td>
</tr>
<tr>
<td>13:45–14:00</td>
<td>Break</td>
</tr>
<tr>
<td>14:00–15:00</td>
<td>Adjuvant treatment</td>
</tr>
<tr>
<td>14:00–14:15</td>
<td>Adjuvant interferon treatment</td>
</tr>
<tr>
<td>14:20–14:35</td>
<td>Future developments of adjuvant treatment of melanoma</td>
</tr>
<tr>
<td>14:40–14:55</td>
<td>Panel discussion</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00–16:00</td>
<td>Targeted therapy of melanoma</td>
</tr>
<tr>
<td>15:00–15:15</td>
<td>Update on targeted therapies in melanoma</td>
</tr>
<tr>
<td>15:20–15:35</td>
<td>Management of adverse events</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>15:40–16:00</td>
<td>Panel discussion: Patient access to new medication initiative of the MWS/global and RSA</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00–16:30</td>
<td>Break</td>
</tr>
<tr>
<td>16:30–17:30</td>
<td><strong>Immunotherapy of melanoma</strong></td>
</tr>
<tr>
<td>16:30–16:45</td>
<td>Overview on immune checkpoint modulators</td>
</tr>
<tr>
<td>16:50–17:05</td>
<td>Future perspectives of immunotherapy</td>
</tr>
<tr>
<td>17:10–17:25</td>
<td>Management of adverse events</td>
</tr>
<tr>
<td>17:30–18:30</td>
<td><strong>Systemic treatment of non-melanoma skin cancers</strong></td>
</tr>
<tr>
<td>17:30–17:45</td>
<td>Basal cell carcinoma</td>
</tr>
<tr>
<td>17:50–18:05</td>
<td>Merkel cell carcinoma</td>
</tr>
<tr>
<td>18:10–18:25</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>18:30</td>
<td>End of sessions</td>
</tr>
</tbody>
</table>
## Saturday, March 4th, 2017

### 08:00–09:00 Prevention of skin cancer

**Chairs:** Adele Green, Dagmar Whitaker

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00–08:15</td>
<td>The role of sunscreens</td>
<td>Adele Green, Brisbane, Australia</td>
<td></td>
</tr>
<tr>
<td>08:20–08:35</td>
<td>Prevention in Australia</td>
<td>Adele Green, Brisbane, Australia</td>
<td></td>
</tr>
<tr>
<td>08:40–08:55</td>
<td>Prevention in South Africa</td>
<td>Dagmar Whitaker, Cape Town, South Africa</td>
<td></td>
</tr>
</tbody>
</table>

### 09:00–10:00 Rare skin tumors

**Chairs:** Roland Kaufmann, Willie Visser

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–09:15</td>
<td>Differential diagnosis of rare skin cancers</td>
<td>Willie Visser, Cape Town, South Africa</td>
<td></td>
</tr>
<tr>
<td>09:20–09:35</td>
<td>Adnexal tumors</td>
<td>Charles Thatcher, Johannesburg, South Africa</td>
<td></td>
</tr>
<tr>
<td>09:40–09:55</td>
<td>Surgery in rare skin cancers</td>
<td>Roland Kaufmann, Frankfurt, Germany</td>
<td></td>
</tr>
</tbody>
</table>

### 10:00–10:30 Break

### 10:30–11:30 Guidelines development and interdisciplinary skin cancer centers

**Chairs:** Dirk Schadendorf, Devan Moodley

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30–10:45</td>
<td>Guideline development for melanoma and NMSC</td>
<td>Dirk Schadendorf, Essen, Germany</td>
<td></td>
</tr>
<tr>
<td>10:50–11:05</td>
<td>European development of interdisciplinary skin cancer centers</td>
<td>Claus Garbe, Tuebingen, Germany</td>
<td></td>
</tr>
<tr>
<td>11:10–11:25</td>
<td>Interdisciplinary cooperation in dermatooncology in South Africa</td>
<td>Devan Moodley, Durban, South Africa</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30–12:30</td>
<td>Follow-up examinations in melanoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Claus Garbe, Dagmar Whitaker</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30–11:40</td>
<td>Follow-up of melanoma in Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claus Garbe, Tuebingen, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:40–11:50</td>
<td>Follow-up of melanoma in South Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dagmar Whitaker, Cape Town, South Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:50–12:00</td>
<td>Follow-up of melanoma in the US</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanjiv Agarwala, Bethlehem, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00–12:30</td>
<td>Panel discussion: Optimizing melanoma follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanjiv Agarwala, Bethlehem, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claus Garbe, Tuebingen, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daniel Vorobiof, Johannesburg, South Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dagmar Whitaker, Cape Town, South Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30–13:30</td>
<td>Lunch break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>End of conference</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Sanjiv Agarwala, MD  
Professor of Medicine  
St. Lukes Cancer Center  
Temple University  
801 Ostrum St  
Bethlehem, PA 18015  
USA  
Phone: +1-610-297-0169  
Email: agarwas@slhn.org

Claus Garbe, MD  
Professor of Dermatology  
Department of Dermatology  
Eberhard Karls University  
Liebermeister Str. 25  
72076 Tuebingen  
Germany  
Phone: +49 7071 2987110  
Email: claus.garbe@med.uni-tuebingen.de

Helen Gogas, MD  
First Department of Medicine  
Laiko Hospital  
University of Athens  
Agiou Thoma 17  
Athens PK 11527  
Greece  
Email: hgogas@hol.gr

Adele Green, MD  
Royal Brisbane Hospital QLD 4029  
300 Herston Rd  
Herston QLD 4006, Brisbane  
Australia  
Phone: +61 7 3362 0234  
Email: Adele.Green@qimrberghofer.edu.au

Jean Jacques Grob, MD  
Professor of Dermatology  
Service de Dermatology and Cancer Research  
Hospital de la Timone  
264 Rue St. Pierre  
13005 Marseille  
France  
Phone: +33-491-388591  
Email: jean-jacques.grob@ap-hm.fr

Axel Hauschild, MD  
Professor of Dermatology  
Department of Dermatology  
University of Kiel  
Rosalind-Franklin-Str. 7  
24105 Kiel, Germany  
Phone: +49 431 50021131  
Email: ahauschild@dermatology.uni-kiel.de

Lucie Heinzerling  
MD, PhD, MPH  
Professor  
Department of Dermatology  
University Hospital of Erlangen  
Ulmenweg 18  
91054 Erlangen  
Germany  
Phone: +49-9131-8539037  
Email: lucie.heinzerling@uk-erlangen.de

Suretha Kannenberg, MD  
NETCARE Kuils River Hospital  
33 Van Riebeeck Rd, Kuils River  
Cape Town, 7580  
South Africa  
Phone: + 27-21-900-6425/18  
Email: info.krcc@mwebbiz.co.za
Roland Kaufmann, MD
Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Germany
Phone: +49-69-63015311
Email: kaufmann@em.uni-frankfurt.de

Rainer Kunstfeld, MD
Professor of Dermatology
Währinger Str. 115
1180 Vienna
Austria
Phone: +43 1 4780033
Email: rainer.kunstfeld@meduniwien.ac.at

Alex Gil Landau, MD
Room 201 Fairfield Medical Suites
Wildernes Road
Claremont, Cape Town 7708
South Africa
Phone: +27-21-674-0853
Email: info@plasticandcosmeticsurgery.co.za

Gary Levy, MD
Johannesburg
South Africa
Email: levy@pixie.co.za

Christopher Philipp Maske, MD
Johannesburg
South Africa
Email: cmaske@gmail.com

Devan Moodley, MD
Durban
South Africa

Bernardo Leon Rapoport, MD
Specialist Physician & Medical Oncologist
The Medical Oncology Centre
P.O. Box 2040, Parklands 2121
South Africa
Phone: +27 (0)11 880 4169/4222
Email: brapoport@rapoport.co.za

Dirk Schadendorf, MD
Professor of Dermatology
Department of Dermatology
University Hospital Essen
Hufelanstr. 55
45147 Essen
Germany
Phone: +49-201-7232430
Email: dirk.schadendorf@uk-essen.de

Peter Scott, MD
Suite C1, Block B, Rochester Place
Medical Centre
173 Rivonia Rd, Sandton
2057, Johannesburg
South Africa
Phone: +27-11-883-2135
Email: peterscott@cinet.co.za

Charles Thatcher, MD
Eighth Avenue, Parktown North
Johannesburg, Gauteng
South Africa
Phone: +27 11 8860112
Email: charlest@histologic.co.za
Willie Visser, MD
Cape Town
South Africa
Email: wvisser@sun.ac.za

Daniel A. Vorobiof, MD
Director
Sandton Oncology Centre
159 Rivonia Rd
Sandton, Johannesburg
South Africa
Phone: +27 11 8830900
Email: voro@global.co.za

Dagmar Whitaker, MD
1 Wytham Ave, Kenilworth Cape Town
Western Cape
South Africa
Phone: +27 21 7624779
Email: dwhitaker@mweb.co.za
Abstracts
All those interested in presenting abstracts at the “Skin Cancer Update 2017 – First International MWS Educational Symposium” are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen as posters. The acceptance of an abstract does not include the conference registration.

Deadline Abstract Submission: January 31st, 2017
Notification of Acceptance of Abstracts: February 13th, 2017

Further information is available online at www.melanomaworldsociety.org/events

Accommodation
MedConcept has obtained special accommodation rates for congress participants. Further information is available online at www.melanomaworldsociety.org/events

Climate
Cape Town is known for its Mediterranean climate with dry warm summers and mild winters. March is a perfect month for a visit in Cape Town. The average temperatures are between 14 °C (57 °F) and 25 °C (77 °F).

CME Credits
An application for CME accreditation will be made.

Exhibition
A commercial exhibition will be held at the congress venue, close to the main rooms.

Insurance
The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.
Language
The official language of the meeting is English. Simultaneous translation will not be provided.

Letter of Invitation
To receive a personal letter of invitation for visa purposes please contact info@medconcept.org.
The invitation is not a commitment on the part of the organizers to provide any financial support.

Meeting Organization

MEDCONCEPT
MedConcept
Gesellschaft für medizinische Projekte mbH
Ms. Mirja Christ
Friedenstraße 58
15366 Neuenhagen b. Berlin, Germany
Phone: +49 (0)3342 42689-30
Fax: +49 (0)3342 42689-40
Email: mirja.christ@medconcept.org or info@medconcept.org
www.medconcept.org

Meeting Venue
The Rotunda
69 Victoria St
Camps Bay, Cape Town, 8001
South Africa
Phone: +27 (0)21 430 4444
Email: res@thebay.co.za
http://www.thebay.co.za/
meeting_rotunda.html

Registration
The meeting website including online registration will be available end of September. You can already register by the registration form given on the last page of the program.
Registration Fees

<table>
<thead>
<tr>
<th></th>
<th>Early registration till Nov. 30th</th>
<th>From Dec. 1st till Feb. 15th</th>
<th>On site</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Africa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Delegates</td>
<td>1,500 Rand</td>
<td>1,900 Rand</td>
<td>2,300 Rand</td>
</tr>
<tr>
<td><strong>Rest of World</strong></td>
<td>300 Euro</td>
<td>350 Euro</td>
<td>400 Euro</td>
</tr>
</tbody>
</table>

After February 15th, 2017 all registrations have to be onsite at the meeting venue.

Cancellation Policy
Cancellations must be received in writing by January 16th, 2017. No refunds will be granted after that date. To cancel a registration, please send an Email to info@medconcept.org. A processing fee of 150 Rand for Africa and 30 Euro for the Rest of the World will be deducted from each cancelled registration. Substitutions are possible and must be received in writing by February 15th, 2017. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org. The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

Visa Requirements
Participants are requested to check with the South African embassy in their home country or with their travel agency for visa requirements.
Gold

- Bristol-Myers Squibb

Silver

- MSD
- Roche

Bronze

- Pierre Fabre

Further Sponsors
Beiersdorf
Fotofinder
Galderma
Genop Healthcare
Provectus
March 3rd–4th, 2017 · Skin Cancer Update 2017
First International MWS Educational Symposium

First Name: ___________________________ Last Name: ___________________________

Professional Title: _______________ Degree: ☐ MD ☐ PhD ☐ RN ☐ PA-C ☐ Other _______

Gender: ☐ Male ☐ Female Speciality: ____________________________________________

Institution: ___________________________ Address: _____________________________

City: _____________ State: ___________ Zip Code: __________ Country: __________

Daytime Telephone: _________________ Fax: _______________ E-Mail: ______________

Fees (VAT included)

<table>
<thead>
<tr>
<th></th>
<th>Early registration till Nov. 30th</th>
<th>From Dec. 1st till Feb. 15th</th>
<th>On site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Delegates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Africa</td>
<td>☐ 1,500 Rand</td>
<td>☐ 1,900 Rand</td>
<td>☐ 2,300 Rand</td>
</tr>
<tr>
<td>Rest of World</td>
<td>☐ 300 Euro</td>
<td>☐ 350 Euro</td>
<td>☐ 400 Euro</td>
</tr>
</tbody>
</table>

Total Amount: __________ Euro/Rand

Payment Method

Bank Transfer: ☐

Credit Card: ☐ MasterCard ☐ Visa ☐ American Express

Credit Card Number: _______________________________________________________

Expiration Date: _________________________________________________________

Security Code CCV: ________________ (MC/Visa – 3 digits on back, AMEX – 4 digits on front)

Cardholder Name: _______________________________________________________

Signature: ______________________________________________________________

Congress Organization

MEDCONCEPT

Gesellschaft für medizinische Projekte mbH
Friedenstraße 58 · 15366 Neuenhagen bei Berlin, Germany
info@medconcept.org · www.medconcept.org
Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40